Newsfeeds - Spark Newswire

2 minute read

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight

Today, 4:45 PM

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.

ACAD

5 minute read

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

By Shanthi Rexaline

Today, 4:45 PM

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.

ABBV

1 minute read

Events
News

Biohaven Data at 2022 American Academy Of Neurology Annual Meeting Demonstrate Leadership In Migraine And Commitment To Advancing Potential New Therapeutic Options In Neurological Diseases

By Benzinga Newsdesk

Today, 4:45 PM

Migraine patients treated with Nurtec ODT had a reduction in total opioid prescriptions filled after initiation of therapy, according to an analysis of real-world administrative claims Single and multiple daily doses

BHVN

1 minute read

Mizuho Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $154

By Benzinga Newsdesk

Today, 4:45 PM

Mizuho analyst Vamil Divan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $144 to $154.

BHVN

2 minute read

Earnings

Biohaven Pharmaceutical’s Return On Capital Employed Insights

By Benzinga Insights

Today, 4:45 PM

Biohaven Pharmaceutical (NYSE:BHVN) brought in sales totaling $190.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 15.81%, resulting in a loss of $199.58 million.

BHVN

1 minute read

Biohaven Pharma: Q4 Earnings Insights

By Benzinga Insights

Today, 4:45 PM

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

BHVN

2 minute read

Biohaven And Pfizer Receive Positive CHMP Opinion For Migraine Treatment

By Benzinga Newsdesk

Today, 4:45 PM

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive

BHVN

4 minute read

Earnings Scheduled For February 25, 2022

By Benzinga Insights

Today, 4:45 PM

Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million.

ACMR

1 minute read

Earnings

Biohaven Pharmaceutical’s Earnings Outlook

By Benzinga Insights

Today, 4:45 PM

Biohaven Pharmaceutical (NYSE:BHVN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate that Biohaven Pharmaceutical will report an earnings per share (EPS) of $-2.04.

BHVN

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

Today, 4:45 PM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL